Document is current
Any future updates will be listed below
-
Authors
Sartorelli, J.
Ng, J.
Rahim, A. A.
Waddington, S. N.
Kurian, M. A.
- License Information
-
More Information
Article History
Received: 2 January 2025
Accepted: 26 January 2025
First Online: 22 February 2025
Declarations
:
: JS has no conflict of interests to declare. JN has held Sponsored Research Agreements with AskBio Europe, Rocket Pharma, Bloomsbury Genetic Therapies and Consultancy contracts with Albion Venture Capital, Helex Bio. JN holds equity in Bloomsbury Genetic Therapies. AAR is a co-founder and has equity in Bloomsbury Genetic Therapies Ltd. Scientific advisory board and has equity in Nuntius Therapeutics. AAR holds patents on “Compositions and methods for treating Parkinson’s Disease (USSN 63/437,437)” and “Gene therapy of Niemann-Pick disease type c (WO2021181096A1)”. SNW Scientific and Manufacturing Advisory Board Member, Forge Biologics and Co-founder of, and equity in, Bloomsbury Genetic Therapies. SNW holds patents on “Compositions and methods for treating Parkinson’s Disease (USSN 63/437,437)”, “Gene Therapy for Dopamine Transporter Deficiency Syndrome (PCT/GB2101958.3)” and “Gene Therapy Vector for eEf1A2 and uses thereof (US application no. 63055775; PCT/EP2020/071028)”. MAK is a cofounder and consultant to Bloomsbury Genetic Therapies, and have received honoraria and consultancy fees from PTC Therapeutics.
